Antibody Phenotypic Profiling via High-Content Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drug discovery pipelines primarily focus on binding affinity and biophysical properties, neglecting the complex biological effects of antibodies on cells, leading to the prioritization of ineffective antibodies in human clinical trials, as simple cell-based assays fail to capture the biological complexity of human diseases.
Innovation Solution
The use of high-dimensional, image-based phenotypic assays and machine learning models, such as neural networks, to profile antibodies and identify their phenotypic effects, allowing for the creation of phenotypic bins that can guide the selection of antibodies for follow-up studies, enhancing sensitivity and consistency in detecting antibody effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If simple cell-based assays are used to measure antibody effects, then the assay complexity and cost are reduced, but the biological complexity of human disease is not captured, leading to ineffective antibodies being prioritized
Solution Approach 1:
The patent transitions from one-dimensional readouts (single measurement parameter) to high-dimensional phenotypic profiling by capturing multiple cellular features simultaneously through imaging. This includes morphological changes, protein localization, cell cycle status, and other phenotypic markers that provide a comprehensive view of antibody effects beyond simple signaling inhibition measurements
Solution Approach 2:
The patent introduces machine learning algorithms as intermediaries that process complex imaging data and extract meaningful phenotypic patterns. These algorithms serve as mediators between the high-dimensional imaging data and the interpretation of antibody effects, enabling the system to handle and interpret the complexity that would be impossible for traditional methods to manage
2Ease of operation
If epitope binning is used to group antibodies, then the grouping process is simplified, but antibodies with different affinities and effects on target protein structure are assumed to behave similarly, causing desirable candidates to be missed
Solution Approach 1:
The patent applies local quality by creating heterogeneous groups within epitope bins based on specific phenotypic characteristics. Instead of treating all antibodies in an epitope bin uniformly, the system identifies and groups antibodies with similar local phenotypic effects (such as specific morphological changes or protein localization patterns), allowing for more precise prediction of antibody behavior while maintaining the overall grouping framework
3Measurement precision
If high-dimensional, image-based phenotypic assays are used to profile antibodies, then sensitivity and consistency in detecting antibody effects are enhanced, but the effort, time, and computational resources required increase
Solution Approach 1:
The patent implements preliminary action by pre-training machine learning models on large datasets of cellular imaging data before actual antibody profiling. This pre-training establishes robust feature extraction capabilities and phenotypic classification frameworks that can be rapidly applied to new antibodies, reducing the time required for actual profiling while maintaining high sensitivity and consistency
Solution Approach 2:
The patent uses digital imaging and computational modeling to create accurate digital copies of cellular phenotypes. These digital representations capture all necessary phenotypic information without requiring physical manipulation or repeated experiments, allowing for rapid analysis and comparison while preserving measurement precision
Data Source
AI summary
Systems and methods that receive as input microscopy images, extract features, and apply layers of processing units to compute one or more sets of cellular phenotype features, particularly antibodies, corresponding to cellular densities and/or fluorescence measured under different conditions. The system is a machine learning architecture having, in one aspect, a deep neural network, typically a convolutional neural network. The deep neural network can be trained and tested directly on raw microscopy images. The system computes class specific feature maps for every phenotype variable using a deep neural network. The system produces predictions for one or more reference antibody variables based on microscopy images within populations of cells.